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19th CardioVascular Summit: TCTAP 2014with a higher risk of bleeding have limited its widespread use. As the rates of early
stent thrombosis are higher especially in the early stages of STEMI, the use of a more
potent DAPT regimen in the initial period could potentially confer the most beneﬁt.
We therefore sought to evaluate the safety and efﬁcacy of a hybrid DAPT regimen
(involving a switch of prasugrel to clopidogrel at 1 month post MI) in STEMI patients
and report on the clinical outcomes.
Methods: From January to August 2012, 141 STEMI patients (94% male, mean age
54 + 9.2 years) were preloaded with 60 mg of prasugrel and 300 mg of aspirin in the
emergency room of our institution prior to PPCI. Patients aged > 75 years, body
weight < 60 Kg and those with previous history of stroke were excluded.
Upon hospital discharge, patients received maintenance doses of 10 mg of prasugrel
and 100 mg of aspirin for the ﬁrst 30 days. At 30 days post MI, prasugrel was stopped
and patients were loaded with 300 mg of clopidogrel followed by 75 mg as mainte-
nance dose (for the remaining 11 months in conjuction with aspirin). The primary
efﬁcacy end point was a composite of death from cardiovascular causes, nonfatal MI,
or nonfatal stroke at 1 year follow-up. The key safety end point was Thrombolysis in
Myocardial Infarction (TIMI) major bleeding at 1 year follow-up.
Results: PPCI was performed predominantly via the radial approach (86%) with
Clexane used as procedural anti-coagulant in 60% of patients (40% received heparin).
Glycoprotein IIb/IIIa inhibitors were administered in 82% of patients with the majority
(64%) receiving drug eluting stent implantation during PPCI.
The primary end point occurred in 6 patients (4.3%) with 4 events (2.8%) occurring
within the ﬁrst 30 days of MI. Death from cardiovascular causes occurred in 3 patients
(2.1%). Non-fatal MI occurred in 2 patients (1.4%) with 1 patient (0.7%) developing a
non-fatal stroke. Stent thrombosis occurred in 3 patients (2.1%) patients with 1 case of
probable stent thrombosis (0.7%) occurring within 30 days of MI.
Bleeding events were observed in 10 patients (7%) with TIMI major bleeding
episode occurring in 3 patients (2.1%). There was 1 bleeding episode occurring in the
setting of coronary artery bypass surgery.
Conclusion: Our preliminary experience showed that a hybrid DAPT regimen in a
selected group of STEMI patients is feasible, efﬁcacious and safe. The long term
clinical outcomes were good with a low incidence of ischaemic and bleeding events.
TCTAP A-031
Platelet Function Test and Bleeding Risk in Patients with Coronary Artery
Disease: A Case-control Study
Ho Fai Daniel Fong
Princess Margaret Hospital, HK, Hong Kong, China
Background: Management of coronary heart disease remains a challenge even with
modern advances. New anti-platelet agents which reduce thromboembolic events in
patients with coronary heart disease were introduced. However, there are concerns about
an increased in bleeding risk for patients taking these new anti-platelet agents. Platelet
function test, such as VerifyNow, claimed to be able to predict bleeding risk. However,
the evidence was limited, especially among the Asian population. This study aimed to
evaluate the use ofVerifyNow to assess bleeding risk. Subjectswith low residual platelet
reactivity, i.e. low PRU value, were hypothesized to have an increased bleeding risk.
Methods: This was a case control study performed in the Princess Margaret Hospital of
Hong Kong. A total of 120 subjects who were taking a P2Y12 inhibitor and had a
VerifyNow test were recruited. The cases were deﬁned as subjects with a PRU value of
less than or equal to 95, a threshold for increased bleeding risk as recommended by
Western studies. The controls were age matched to the cases. The primary outcome was
the increase in bleeding risk associated with a low PRU value at 30 days. The secondary
outcomewas the increase in bleeding risk associatedwith a lowPRUvalue at 1 year. The
use of the percentage of platelet inhibition was also evaluated as a secondary outcome.
Multivariable logistic regression was used to obtain the odds ratio of the low PRUgroup.
Results: Bleeding events occurred more frequently in the low PRU group. At 30 days,
31.7% of subjects among the case had a bleeding event while 43.3% of the cases had a
bleeding event at 1 year. The majority of these bleeding events were minor bleeding,
such as easy bruising. After adjusting for confounders, there was no statistically
signiﬁcant increase in bleeding risk among those in the low PRU group at 30 days or 1
year. Subjects with a high percentage of platelet inhibition (>50%) was also not
associated with a statistically signiﬁcant increase in bleeding risk.
Conclusion: A low PRU value was not associated with an increased bleeding risk at 30
days. Thus the VerifyNow test was not shown to be useful in assessing the bleeding risk of
patients in anAsian population, contrary to theﬁndings fromWestern literature.A possible
explanation was that the VerifyNow threshold for predicting bleeding might be higher
among the Asian population. The deﬁnition for low residual platelet reactivity might be
different in our locality. A larger sample size might also be needed. Further studies are
needed to evaluate whether a different cut off is more optimal for the Asian population.
TCTAP A-032
Comparison of Platelet Reactivity and Clinical Outcomes in Patients Treated
with Clopidogrel and Coronary Intervention
Sang Yeub Lee, Ju-Hee Lee, Sang Min Kim, Jang-Whan Bae, Kyung-Kuk Whang,
Dong-oon Kim, Myeong-Chan Cho
Chungbuk National University Hospital, Cheongju, Korea (Republic of)
Background: Platelets are associated with vascular occlusive event. High on-clopi-
dogrel platelet reactivity (HPR) is associated with recurrent thrombotic events after
percutaneous coronary intervention (PCI). We evaluated platelet reactivity measured
by the VerifyNow P2Y12 assay and clinical outcomes in patients receiving clopi-
dogrel and PCI of real world practice.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAMethods: We recruited A total of 878 consecutive clopidogrel-treated patients un-
dergoing emergent or elective PCI. The main outcome measures were cardiovascular
(CV) death, deﬁnite/probable stent thrombosis (ST), nonfatal myocardial infarction
(MI), coronary revascularization and a composite end point of ischemic events. We
assessed Platelet reactivity 12 hours later by measuring P2Y12 reactivity unit (PRU)
with VerifyNow P2Y12 assay (Accumetrics, San Diego, California). High platelet
reactivity (HPR) was deﬁned as PRU value  240 or 280.
Results: In total, 877 consecutive patients were enrolled. Patients with HPR were 454
(Male, 284). In all patients, coronary stent was implanted. All patients received clo-
pidogrel pretreatment (300mg loading dose), received a maintenance dose of 75 mg
daily. The composite end points of the study at follow-up of 12 months were CV
death, nonfatal MI, and coronary revascularization. At a 12-month follow-up, we
found 85 ischemic events (26 CV deaths [3.4%], 11 nonfatal MIs [1.4%]) and 56
target-vessel revascularizations (7.1%). The composite event rate of patients with HPR
(PRU > 240) was signiﬁcantly higher (7.5% vs 4.3% (p ¼ 0.047)) than the patient
with normal value. In survival analysis, there was no signiﬁcant difference between
patient with HPR (PRU > 240) and normal reactivity. But between patient with HPR
(PRU > 280) and normal reactivity, the survival rate free from the primary end point
was signiﬁcantly lower in patients with HPR (p ¼ 0.014, Generalized Wilcoxon test).
Conclusion: High on-clopidogrel platelet reactivity tested by VerifyNow predict
coronary adverse event in patients after PCI. In Korean, we seem to have to raise the
optimal cutoff value of PRU to predict future coronary event.
TCTAP A-033
Reappraisal of Pharmacodynamic Effect of Adjunctive Cilostazol and High-dos
Clopidogrel in East Asian ACS Patients
Young-Hoon Jeong, Yongwhi Park, Jin Sin Koh, Jin-Yong Hwang
Gyeongsang National, Jinju, Korea (Republic of)
Background: Compared with Westerners, East Asians have shown different thera-
peutic level of platelet reactivity (PR) regarding post-PCI ischemic and bleeding
events. We also reported different therapeutic level for East Asians (35% < 20 mM
ADP-PR < 70%). We reappraised the pharmacodynamic effect of adjunctive cil-
ostazol and high-dose clopidogrel in East Asians based on this criteria.
Methods: PCI-treated ACS patients were assigned to either clopidogrel 150 mg/d
(DOUBLE; n¼139) or cilostazol 100 mg bid + clopidogrel 75 mg/d (TRIPLE; n¼136)
on top of aspirin. PR was measured at least 30-day follow-up with light transmittance
aggregometry. Primary endpoint was the prevalence of HPR at follow-up.
Results: DOUBLE and TRIPLE together showed low prevalences of HPR (9.4% and
2.2%, respectively). Although the level of PR in TRIPLE increased according to the
number of CYP2C19 loss-of-function (LoF) allele (p¼0.015), HPR risk was almost
overcome irrespective of CYP2C19 phenotype (p¼0.633). The level of PR and HPR
risk in DOUBLE increased proportionally depending on CYP2C19 phenotype
(p<0.001 and p¼0.006, respectively). In multivariate analysis, carriage of 2
CYP2C19 LoF alleles only increased HPR risk by 8.5-fold in DOUBLE.
Conclusion: Our results support clinical usefulness of TRIPLE in East Asians based
on pharmacodynamic data. Clinical efﬁcacy and safety of more potent P2Y12 in-
hibitor, prasugrel and ticagrelor, must be reevaluated separately in this unique race.TCTAP A-034
Observational Studies of Bleeding and Thrombotic Events in Acute Coronary
Syndrome Patients Between Different Metabolizer of Clopidogrel
Wen Duo Zhang, Fu Sui Ji
Beijing Hospital, Beijing, China
Background: Compared with CYP2C19*1 carriers，CYP2C19*2,*3 carriers have
a higher risk of stent thrombosis in clopidogrel-treated patients. ThereforeL/Antiplatelet Agents and Anticoagulants S9
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19th CardioVascular Summit: TCTAP 2014CYP2C19*2,*3 carriers with cardiovascular diseases and ready to receive PCT are
suggested to pay more attention to stent thrombosis when using clopidogrel. However,
there are differences in cardiovascular and bleeding events between different metab-
olizer of clopidogrel with different CYP2C19*2,*3 Genotype. We surpassed that there
are no statistically signiﬁcant between different metabolizer of Clopidogrel of
bleeding and thrombotic events in acute coronary syndrome patients.
Methods: We enrolled 208 acute coronary syndrome patients from 11/01,2012 to 10/
01,2013, which enrolled in our department of cardiology of Beijing Hospital. All the
patients underwent successful percutaneous coronary drug-eluting stent implantation.
CYP2C19 gene Genotype were detected in all patients, and according to test results
into three groups (Extensive metabolizer, Intermediatemetabolizer, Poor metabolizer).
All candidates were all receiving dual antiplatelet therapy ( clopidogrel 75mg QD plus
aspirin 100mg QD), were given loading dose of clopidogrel 600 mg and aspirin
300mg, All the patients were followed three months and not changed the daily dose of
clopidogrel and aspirin. The cardiovascular endpoints 、stent thrombosis and bleeding
events rates were statisticted by SPSS 16.0.
Results: After taking clopidogrel after stent implantation, cardiovascular event rates
of three groups (Extensive metabolizer, Intermediatemetabolizer, Poor metabolizer)
were 28.6%, 26.0%, 25.0%, P ¼ 0.926; bleeding event rate of three groups were
12.0%, 14.5%, 10%, P ¼ 0.867; thrombotic event rates of three groups were 5.3%,
13.0%, 9.1%, P ¼ 0.256. All clinical endpoint events were not statistically signiﬁcant.
Conclusion: We found that there no statistically signiﬁcant different about clinical
events between three metabolizer type groups. However, because the number of cases
were not large, so itwas early tomake up conclusions that it is not to change the daily dose
of clopidogrel the determined by CYP2C19 gene Genotype. And it need more research.S10 JACC Vol 63/12/Suppl S j April 22–25, 2TCTAP A-035
Aspirin Versus Clopidogrel Following Dual Antiplatelet Therapy on the Era of
Drug-eluting Stents
Taek Kyu Park, Young Bin Song, Jeong Hoon Yang, Joo-Yong Hahn,
Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Hyeon-Cheol Gwon
Samsung Medical Center, Seoul, Korea (Republic of)
Background: Dual antiplatelet therapy (DAPT) for at least 12 months is currently
recommended in all patients with drug-eluting stent (DES) implantation. However,
there are few studies compared between aspirin monotherapy versus clopidogrel
monotherapy after DAPT in patients implanted with DES. We sought to compare the
efﬁcacy and safety of clopidogrel versus aspirin following 12-month of DAPT in
patients undergoing percutaneous coronary intervention (PCI) with DES.
Methods: An observational study was conducted on consecutive patients receiving
DES at Samsung Medical Center in Korea between January 2003 and December 2010.
Landmark analyses were performed among patients who were event-free (no death,
myocardial infarction [MI], revascularization, or cerebrovascular accident [CVA]) at
12-month follow-up. At this point, patients were divided into two groups: aspirin (n ¼
2,477, 76%) versus clopidogrel (n ¼ 784, 24%). Primary outcome was a composite of
cardiac death, MI, or CVA during follow-up. We used weighted Cox proportional
hazards models using inverse-probability-of-treatment weighting.
Results: Clinical, angiographic and procedural characteristics revealed more comor-
bidities and more complex lesions in clopidogrel group compared with aspirin group.
During median follow-up of 59 months, 166 primary composite events were occurred.
In multivariate analysis, clopidogrel was associated with a risk reduction in a com-
posite of cardiac death, MI, or CVA (p ¼ 0.006). A tendency of risk reduction was
also seen in each of cardiac death, MI and CVA.
Conclusion: Following 12-month of DAPT, clopidogrel monotherapy may be asso-
ciated with a risk reduction of recurrent ischemic events compared with aspirin in
patients undergoing PCI with DES.TCTAP A-036
Dyspnoea - Is It a Serious Issue with Ticagrelor?
Paramdeep Singh Sandhu1, Upendra Kaul2
1GGS Medical College, Faridkot, India, 2Fortis Escorts Heart Institute And Research
Centre, New Delhi, India
Background: Studies that compared the reversible P2Y12 inhibitor ticagrelor with the
irreversible inhibitor clopidogrel, dyspnea was observed more frequently with tica-
grelor versus clopidogrel-treated patients (13.8% vs. 7.8%). Out of patients presenting
with dyspnea it was stopped in only less than 1%. How serious is it? How do the
Indian patients respond to it-is not known.
Methods: All the patients who presented in emergency room with diagnosis of
Acute Coronary Syndrome (ACS) and started on ticagrelor along with aspirin as
dual antiplatelet therapy were analysed and prospectively followed for the period of
6 months.
Results: In our experience since October 2012, 166 Acute Coronary Syndrome (ACS)
patients with the mean age of 628years were started on ticagrelor along with aspirin
as dual antiplatelet therapy. Of these 72% were male, 35% had hypertension, 42%
were diabetic, 30% had dyslipidemia and 20% had history of smoking while none of
the patient had bronchial asthma or chronic obstructive airway disease. These patients
were followed up at one week, one month and 6 months. Of 166 patients 31 patients
had complaints of dyspnea 95% of times at one week of follow up. Of all patients
complaining of dyspnea ﬁve presented to the emergency department and were
extensively evaluated to rule out other differentials. Out of 31 patients with dyspnea
20 i.e. 12% of total and 64.5% of patients with dyspnea ticagrelor had to be stopped,
following which patients improved. In the remaining 11 patients dyspnea improved
with time and no patient was discontinued ticagrelor after one month of follow up due
to dyspnea.
Conclusion: Ticagrelor-related dyspnea is more frequent and more severe in intensity
in Indian population as compared to the population reported in PLATO study. It is the
main reason for the discontinuation of ticagrelor in patients of ACS in whom it was
started as a dual antiplatelet regimen.014 j TCTAP Abstracts/ORAL/Antiplatelet Agents and Anticoagulants
